- 1 Absolute quantification of synuclein proteoforms in plasma in
- 2 patients with Synucleinopathies by LC-MRM mass spectrometry
- 4 Pons Marie-Laure^{1, 2}, Vignon Margaux¹, Vialaret Jérôme¹, Mondesert Etienne¹,
- 5 Moreau Stéphane², Lehmann Sylvain¹ and Hirtz Christophe¹
- ¹ IRMB, Univ Montpellier, INM, INSERM, CHU Montpellier, (LBPC-PPC), Montpellier,
- 7 France

3

- ² Shimadzu Corporation, Albert-Hahn-Straße, Duisburg Germany
- 9 marielaurepons43@gmail.com (+33 4 67 33 71 73), margaux.vignon@umontpellier.fr
- 10 (+33 4 67 33 04 20), j-vialaret@chu-montpellier.fr (+33 4 67 33 71 73), e-
- mondesert@chu-montpellier.fr (+33 4 67 33 83 46), sm@shimadzu.eu (+49-203-
- 12 76870), sylvain.lehmann@umontpellier.fr (+33 4 67 33 71 23) and
- christophe.hirtz@umontpellier.fr (+33 4 67 33 04 20).
- 14 Corresponding author: Pons Marie-Laure, marielaurepons43@gmail.com (+33 4 67
- 15 33 71 73).

16

Abstract

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Background: Synucleinopathies include Parkinson's disease (PD), Lewy body dementia (LBD) and Multiple system atrophy (MSA). Most studies of synucleinopathies rely on immunoassays to quantify total or oligomeric alpha synuclein. Immunoassay results are variable due to the inconstant nature of antibodies and different studies found higher, lower or equal levels of alpha synuclein between PD and control patients in biological matrixes. Mass spectrometry, has less inherent variability. Methods: Therefore, we developed the first reliable and validated mass spectrometry method to quantify synuclein proteoforms in human plasma using liquid chromatography coupled to mass spectrometry with multiple reaction monitoring mode (LC-MRM) mass spectrometry. Results: The study followed European and International guidelines (Food and Drug administration and European Medicines Agency) and paves the way for precise multiplex quantitation of synucleinopathies. Using a cohort of 143 patients with synucleinopathies and controls we found a peptide ratio and combination between αsyn EQVTNVGGAVVTGVTAVAQK and α/β-syn EGVLYVGSK peptides that discriminated PD patients from the other diseases (LBD, MSA and controls). The sensitivity and specificity (Area Under ROC Curve) of the method to distinguish between patients with PD and control patients was 0.84 and 0.76 (0.787), for PD vs LBD the values were 0.7 and 0.68 (0.743), and 0.85 and 0.85 (0.831) for PD vs MSA. Conclusions: The developed and validated LC-MRM method presented here could be used in clinical to discriminate PD from other synucleinopathies and control patient.

- 42 Keywords: Parkinson's disease, alpha synuclein, immunoassay, mass spectrometry,
- proteoforms, ratio and combination of peptides.

Introduction

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Synucleinopathies are a group of pathologies that share cognitive, motor, non-motor symptoms and molecular inclusions composed of alpha synuclein. The three most well-known and common such pathologies are Lewy bodies Dementia (LBD), Parkinson's disease (PD) and multi system atrophy (MSA)¹. There are three kinds of synuclein: alpha, beta and gamma synuclein, that are all present in pre-synaptic terminals in dopaminergic neurons. Alpha synuclein inclusions, called Lewy bodies and Lewy neurites, are made of aggregated, fibrillar, phosphorylated, ubiquitinated and truncated alpha synuclein species. These inclusions are retrieved in the cytoplasm of the dopaminergic neurons for PD and LBD pathologies and found in oligodendrocytes for MSA patients¹. Lewy bodies are responsible for the neurodegeneration observed in synucleinopathies². Therefore, this protein and its proteoforms have been proposed as biomarkers for these pathologies³. Synuclein proteoforms include serine 129 phosphorylated, some C-terminal truncations and ubiquitination sites or alternatively spliced alpha synuclein isoforms with 126, 112, 98 and 41 amino acids⁴. Indeed, the alpha synuclein spliced variants have been found in different mRNA level in synucleinopathies. α-syn alternative proteins also arise from a reading frameshift (+2 instead of +1) resulting in different and shorter protein than the full length alpha synuclein (140 aa). This type of species could potentially play a role in the pathogenesis of neurodegenerative disease⁵. Beta synuclein is not detected in aggregates or fibrils in brains with synucleinopathies and has a lower propensity to aggregate than alpha synuclein due to the absence of

the 73-83 AA part of the non-amyloid component domain⁶. Gamma synuclein has 67 been detected in fibril form in PD brains. 68 69 For several years, synucleins have been studied, and especially alpha synuclein, due 70 to their potential biomarker value in neurodegenerative disorders. So far, detection 71 and quantification of synucleins (total, oligomeric and phosphorylated at S129) in 72 human biological fluids has mainly been achieved via antibody-based assays such as 73 ELISA ^{3,8}. This approach may undergo some bias due to nonspecific detection and 74 antibody affinity variability. Indeed, immunoassay kits gave highly variable results in 75 absolute concentration and with alpha synuclein level retrieved in biological fluid (cerebrospinal fluid⁹, plasma and saliva). 76 77 To counteract antibody-based method (ELISA) issues, clinical mass spectrometry 78 (MS) approaches have been successfully developed to improve protein and proteoform quantification¹⁰. Indeed, MS is a powerful tool thanks to accurate, specific 79 and multiplex quantitation. These performances are due to the analysis of mass on 80 charge (m/z) of ions from proteotypic peptides after sample ionisation¹¹. In multiple 81 reaction monitoring (MRM), at least three transitions, corresponding to the 82 fragmentation of the precursor ion into products ions, are monitored¹². 83 In conclusion, the concentration differences of alpha synuclein observed in 84 synucleinopathies in CSF, the lack of study using MS quantification (3), the risk of 85 interference by blood contamination during lumbar puncture 13 and the high 86 expression of alpha synuclein in erythrocyte¹⁴, supports the notion that total alpha 87 synuclein in CSF is not a useful diagnostic biomarker for synucleinopathies⁷. 88

Here we present a validated and targeted mass spectrometry method to quantify synucleins proteoforms in plasma patient samples with synucleinopathies. This quantification method was compared with sensitive immunoassay measurement.

Materials and methods

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Reagents and internal standards

Recombinant human full-length alpha synuclein (α-syn) and the recombinant fulllength α-syn with uniform ¹⁵N-label came from LGC (Teddington, UK). The recombinant beta and gamma synuclein (β-syn and y-syn) with uniform ¹⁵N-label were purchased from Promise Advanced Proteomics (Grenoble, France). The beta and gamma recombinant light form came from Anaspec (Fremont, California, USA) and Interchim (Montluçon, France) respectively. Light protein standard concentration was determined for α-syn by electrochemiluminescence with the U-PLEX Human α-Synuclein immunoassay kit purchased from MesoScale Discovery system (Rockville, Maryland, USA). MS grade Trypsin/LysC, rLysC, Glu-C and Lys-N were purchased from Promega GmbH (Walldorf, Germany). Ammonium bicarbonate, perchloric acid, trifluoroacetic acid and human serum albumin (HSA) were ordered from Sigma Aldrich (Saint Quentin Fallavier, France). RP-W Cartridge tips were purchased from Agilent technologies (Santa Clara, California, USA). MS-grade liquid chromatography solvents: acetonitrile, water and formic acid were purchased from Biosolve (Dieuze, France). AQUA (absolute quantitation) peptides for α-syn-126/98; α-syn-112/98 and α-syn-41 came from Thermofisher scientific (Lincoln, Massachusetts, USA) with a purity of 99%. Specific peptides of the alternative α-syn and its mutated form were also purchased from Thermofisher scientific (Lincoln, Massachusetts, USA) with a

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

purity of 95%. Goat serum (capra hircus) was ordered from Clinisciences (Nanterre, France). Stock Solutions, Calibration Standards, and Quality Control (QC) samples Protein and peptide standards were dissolved in 50 mM ammonium bicarbonate to a final concentration of 1µg/µl. Aliquots of 10 µl were dispensed into low proteinbinding Eppendorf tubes and stored at -20 °C or -80 °C, according to the suppliers' instructions. Method development and validation were performed on plasma QC samples at three concentration levels: low (45 ± 6.2) ng/ml, medium (87 ± 16.9 ng/ml) and high (230 ± 30.4 ng/ml), quantified by electrochemiluminescence (MesoScale Discovery). Patient samples from the laboratory biobank were thawed at 4°C for one hour. They were put in a 50 ml falcon and mixed for several minutes. They were then realiquoted (50µl per tube) and stored at -80°C until analysis. MS Calibration 9 points of calibration were prepared by diluting recombinant light α-syn, β-syn and γsyn standards into goat (capra hircus) serum. Calibration ranges (detailed in Table S2 in supplemental data) were as follows: [0-5571] ng/mL for α-syn, [0-410] ng/mL for β-syn and [0-1401] ng/mL for y-syn. The calibration range for labelled peptides (AQUA) including N-terminal peptide, peptides from α-syn isoforms, and peptides from α-syn alternative protein, were performed separately on 8 points and the concentration of each peptide is described in Table S3 in supplemental data. Peptide concentrations were calculated based on the calibration curve (weighting 1/x2) using Skyline software.

Sample Preparation

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

95 µl of plasma samples were thawed on ice for 1 hour. Then 855 µl of deionised water was added. Samples were then supplemented with 5.7 µl of 10 ng/µl internal standard of recombinant labelled U-15N alpha, beta and gamma synuclein in 50 mM ammonium bicarbonate. Samples were mixed and the proteins were precipitated by incubation on ice for 15 minutes with 142.5 µl of 70% perchloric acid. After incubation, samples were spun at 16,000 g for 15 min at 4°C, and the supernatants were collected into new LoBind tubes with the addition of 95 µl of 1% trifluoroacetic acid. After a volume reduction by vacuum-drying at room temperature (Speedvac, Labconco), the supernatants were cleaned up on RP-W cartridges using the AssayMap Bravo (Agilent technologies) into a LoBind 96 deep well plate. The cartridges were washed out with water at an aspiration speed of 10 µl/min and then samples were loaded on the cartridges at 5 µl/min. Proteins were washed out on bravo tips with 10% acetonitrile and 0.1% formic acid at 10 µl/min and eluted with 45% acetonitrile and 0.1% formic acid at 5 µl/min. Samples were evaporated dry at room temperature under vacuum for 1h30 using a Speedvac. The samples were reconstituted with 20µl of 50mM ammonium bicarbonate. Finally, 7 µl of 1µg/µl trypsin/lysC were added. Plasma samples were incubated for 4 hours at 37°C with gentle agitation (450 rpm). After incubation, 0.5 µL of formic acid was added to the samples.

Liquid chromatography-mass spectrometry multiple reaction monitoring analysis

Samples were analysed using a Shimadzu liquid chromatography system (Mikros) and a triple quadrupole - Shimadzu 8060 mass spectrometer (Duisburg, Germany) in

positive ionization mode. 15µl of sample were injected on a ZORBAX SB-Aq (1 x 150 mm, 3.5 µm) column from Agilent technologies, at 35°C. The mobile phase A was composed of water with 0.1% of formic acid and the mobile phase B was composed of acetonitrile with 0.1% of formic acid. The solvent gradient consisted of a slow increase of the organic solvent (phase B) from 0% to 30% over 30 min. Total run time for the analysis was 40 min at a flow rate of 50μ l/min. The minimum dwell time used was 20 ms per peptide. The ion source parameters were 3 L/min for the nebulizing gas flow, 10 L/min for the heating gas flow, 300° C for the interface temperature, 250° C for the desolvation line temperature, 400° C for the heat block temperature and 10L/min for the drying gas flow. Between three and six transitions were acquired for each peptide in biological samples. Peptide position, selection and transitions of the synucleins are described in Table S1 in supplemental data. The concentration of the α -syn and β -syn peptides was determined by comparing unlabelled and labelled peptides with LC-MRM analysis.

Analytical method validation

The intra and inter-assay repeatability was determined by analysing three QC plasma at three different levels of α -syn (high, medium and low) per day over 4 days. Sample stability was determined by analysis three aliquots of goat serum thawed on ice or at room temperature for 6h. In addition, three QC plasma were stored until 48h into the liquid chromatography autosampler at 4°C. Dilution and parallelism stability was determined by dilution of goat serum with ammonium bicarbonate up to fourfold. Matrix effect was determined by comparing the MS signal between spiked normal goat serum (n=3) with heavy recombinant standards after digestion and spiked solvent (n=3) after digestion at the same concentration.

The lower limit of quantification was defined as the lowest concentration with a CV superior to 20% and a signal to noise ratio > 5.

Immunoassay

Plasma samples were analysed by immunochemiluminescence assay with a MesoScale Discovery. Plasma samples were diluted 200-fold for the determination of the total alpha synuclein concentration. All measurements were performed according to the manufacturer's instructions. Antibodies were directed against α -syn C-terminal part (110-125) for capture (rabbit monoclonal antibody) and the mouse monoclonal detection antibody was against amino acids 15-125.

Patients and Biofluid Collection

All the participants gave their written consent to be enrolled in the study which was approved by the Montpellier University Hospital's regional Ethics Committee. General characteristics of the 143 patients are presented in Table 1. Mean age of the population was 71 (\pm 8.2) years, and 65 % were men. The cohort was divided in three disease groups: PD (n=82), LBD (n=32) and MSA (n=8) and a group of control patients (n=21). Control patients suffered from non-neurodegenerative diseases such as neurologic disorders including neuropathic affections (23.8 %), vascular affections (28.6 %), immunologic affections (28.6%) and hydrocephalus (19.0 %). Exclusion criteria for the control group was an abnormal Alzheimer biomarker profile (i.e. low Aß 42/40 ratio and increased tau/ptau protein concentration). Regarding patients with Parkinson's diseases, diagnosis was determined on average 11 (\pm 7.4) years before analysis. At diagnosis 41.9% had cognitive impairment and 69.7% presented non motor signs. Mean Hoehn and Yahr score (corresponding to the Unified Parkinson's Disease Rating Scale II

and III scores were respectively, 19.7 (± 11.2) and 36 (± 18.9), corresponding to a light or moderate motor impairment. Plasma collected by venous puncture were stored at the Montpellier Neurobank (#DC-2008-417 of the certified NFS 96-900 CHU resource center BB-0033-00031). Authorization to handle personal data was granted by the French Data Protection Authority (CNIL).

Data analysis

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

The extraction of LC-MS chromatograms of synucleins peptides for quantification was realized using Skyline Software (20.1.0 version) and LabSolutions Insight Browser. Liquid chromatography-mass spectrometry with multiple reaction monitoring mode analyses were launched with LabSolutions software (5.99 version).

Statistical analysis was performed with MedCalc (19.0.3. version) and the normality of the data set were checked by Shapiro-Wilk test. Comparisons between the two groups were performed by Mann Whitney Wilcoxon method and clinical performance **ROC** were assessed by curve. Α statistical model: (α-syn [EQVTNVGGAVVTGVTAVAQK]*-0.011268 + α/β -syn [EGVLYVGSK] * 0.0096545) that defines the results was investigated by logistic regression with 'backward' and 'enter' methods. To select the model within the two methods, we set the following parameters: p-value <0.05, a minimal number of variables (2) and if both logistic regression methods gave the same coefficient result.

Results

Method development and optimization

To quantify alpha synuclein, we selected all the proteotypic peptides, except the C-terminal part that covers about 70% of the protein sequence. The C-terminal peptide

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

is a long peptide (38 aa), mainly composed of acidic residues and many posttranslational modifications (phosphorylation, nitration and truncations) that impact the MS signal. In plasma, this C-terminal peptide was constantly under the limits of quantification. All the peptides and transitions were selected based on the sensitivity and specificity observed in the biological sample compared to the spiked internal labelled standards. All the MS parameters (tension applied in all quadrupoles) were optimized for synuclein and haemoglobin peptides and are described in Table S1 in supplemental data. We applied the same methodology for β -syn and γ -syn. The entire workflow for the liquid chromatography-mass spectrometry with multiple reaction monitoring mode analysis of the alpha synuclein peptides in plasma is illustrated in Figure 1. Analytical method validation Both β-syn and y-syn were constantly below the limit of quantification in the patient samples and plasma QC samples at all three levels of α-syn concentration (high, medium and low). The alternative splicing isoforms and alternative α-syn peptides were also under the limit of quantification. α -syn and α/β -syn common peptides were detected and quantified in all QC and patient samples.

Intra and Inter-assay repeatability was less than 20 % for alpha synuclein peptides in low concentration QCs, except for TVEGAGSIAAATGFVK peptides that were at 22% in low QCs. In medium level QCs the coefficient of variation (CV) was \leq 16% and \leq 14% in high QCs for α -syn peptides, except for EGVVHGVATVAEK and (ac)MDVFMK peptides (CV >30%). Therefore, these peptides were excluded from further clinical validation.

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

The limit of quantification range was between 6.45 and 19.35 ng/ml for α-syn peptides and α/β-syn common peptides. The linearity ranged from 0 to 5571 ng/ml for α-syn peptides. The linearity range was from 0 to 5981 ng/ml for α/β-syn common peptides. The synuclein peptides was stable when stored at 4°C until 48h, stable when thaw on ice until 6h and 4h at room temperature The analytical validation parameters of the synuclein peptides are detailed in supplemental data in Table S4 and S5. Clinical validation In total 143 plasma samples were quantified, divided in 4 groups: the PD group (n=82), the MSA group (n=8), the LBD group (n=32) and the control group (n=21). All samples were acquired by MS and immunoassay. Details of the studied population are summarized in the Table 1. To determine the clinical performance, we evaluated the area under ROC curve (AUC), the sensitivity and specificity, and the p-value to distinguish between pathological groups. The clinical performance results for alpha synuclein peptides in plasma patient samples are presented in details in Table 2. All peptides were able to distinguish PD patients from control patients, except for the α-syn TVEGAGSIAAATGFVK peptide. The best performance peptide was α/β-syn EGVLYVGSK followed by α-syn QGVAEAAGK. Indeed, these peptides also separated the LBD group from PD and controls groups. The α/β-syn EGVLYVGSK peptide discriminated MSA patients from controls and gave the best clinical performance to distinguish PD and control patients. Respectively, the sensitivity and

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

specificity were 0.84 and 0.76 for PD vs control. The clinical performance of the α/βsyn EGVLYVGSK peptide (PD vs control) are illustrated via ROC curve in supplemental data in Figure 1. No peptides discriminated the PD group from the MSA group. To counteract this issue, we applied a model combination of peptides. Thanks to logistic regression, a peptide combination was found comprising these two following peptides: α-syn EQVTNVGGAVVTGVTAVAQK and α/β-syn EGVLYVGSK, with the following coefficient -0.011268 and 0.0096545, respectively. The data comparison graph between groups for the peptide combination are described in Figure 2. The obtained combination of these two peptides gave good discrimination of the PD group from the MSA patients (P=0.0021). Due to their opposite coefficient signs, we also investigated a ratio of the two alpha syn peptides to distinguish the four groups. The best clinical performance for distinguishing PD from DLB or MSA was obtained with the peptide combination. Indeed, a sensitivity and specificity of 0.7,0.68 and 0.84, 0.85 respectively were obtained. The ROC curve describing the clinical performance of the peptide combination in PD vs LBD is demonstrated in Figure 3A, and similarly, Figure 3B describes the clinical performance of the peptide combination in PD vs MSA Immunoassay quantification The same plasma cohort has also been quantified by sensitive immunochemiluminescence assay. The data comparison graph between disease is presented in supplemental data Figure 2. No significant differences in α-syn level quantified by immunochemiluminescence assay were observed between diseases. A

slightly lower level in the control group compared to the PD group was observed.

Correlation

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

All the alpha and beta synuclein peptides were correlated together (r>0.7). No correlation was found between patient characteristics (age, sex, sampling date) and synuclein peptides (including combinations and ratios) with -0.5<r<0.5. Also, no correlation between MS quantitation and immunochemiluminescence quantitation was found (-0.3<r<0.3). No correlation between motor (UPDRS II, III or V) or non-motor symptoms and cognitive symptoms were observed (-0.3<r<0.3).

Discussion

In this study MS clinical validation allowed us to observe a significant increase of five α-syn peptides, in PD plasma patients compared to control. The same patients were quantified by sensitive immunoassay for total alpha synuclein and no significant difference was observed between disease groups. The most important difference between these two methods is the variability introduced by the use of antibodies in immunoassays. In this case, the antibodies used targeted the C-terminal part of the proteins, which is problematic as this undergoes numerous post-translational modifications and truncations. These variations impact the total concentration of this protein as perceived by immunoassay¹⁵. Indeed, the immunoassay readout did not correlate with any of the alpha synuclein peptides we observed in our MS pipeline. However, all the synuclein peptides correlated amongst themselves indicating that they are a robust measure of alpha synuclein levels. One of our main aims of our study was to discriminate different synucleinopathies and controls. Regarding this particular point, we investigated a peptide combination and a ratio of alpha syn peptides and succeeded in differentiating PD from other groups with good sensitivity and specificity (more than 80% for sensitivity and

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

between 70% and more than 80% for specificity depending on pathologies). This strategy was reminiscent of studies of AD that found that the ratio between amyloid peptides (Aβ40/42) can detect the disease. The ratio of Aβ40/42 in AD allows a better discrimination and enhanced clinical performance of AD patients even at prodromal stage compared to the quantification of the two separated peptides¹⁶. There may be some biological parallels here as alpha synuclein has already shown some similarity in aggregation mechanism with the amyloid beta peptides. Indeed, the peptides comprised in our peptide combination for alpha synuclein come from differentially affected parts of the protein. In the first place the α/β-syn EGVLYVGSK peptide (position 35-43 on sequence), is part of the N-terminal region. McGlinchey et al. 2021¹⁷ have described those residues 36-40 as being important for full-length structure and for the formation fibrils. These results mean that the N-terminal part can modulate the mechanism of amyloid formation and the molecular interactions of fibril assembly¹⁷. On the other hand the α-syn EQVTNVGGAVVTGVTAVAQK peptide (position 61-80 on sequence), is part of the non-amyloid component domain that constitutes the fibril core of the protein and is responsible of the aggregation process^{17,18}. While tantalizing, the utility of peptide combination/ratio will now need to be confirmed in a larger study. For example the specificity with which we can distinguish PD from MSA patients will need confirmation in a larger cohort, as MSA is rare with a prevalence estimated between 0.6 and 1.6 case per 100 000 habitants per year¹⁹. For PD, misdiagnosis is estimated at approximatively 25 % and with well-established biomarkers, the disease could be detected 10 years earlier than it currently is^{20,21}. We also note that none of our lead peptides correlated to PD severity (Unified Parkinson's Disease Rating Scale UPDRS II, III and V). This could be due to the fact

that most of the PD patients in our cohort were similarly affected with only light or moderate evolution.

Conclusion

Here we developed for the first time a validated method for the quantitation of synuclein peptides in plasma patients with synucleinopathies by a targeted and multiplex liquid chromatography coupled to mass spectrometry method. We established a combination and ratio of alpha synuclein peptides, that distinguishing MSA from PD patients with good sensitivity and specificity (more than 80% for each). The AUC or sensitivity and specificity obtained for the ratio and combination were satisfying and similar to the clinical performance obtained for A β 40/42 ratio that is use in AD clinical routine diagnostic. We can also distinguish PD patients from control and LBD pathology which is a strong finding and might

clinical diagnosis but they may also be important for treatments targeting abnormal

revolutionize the synucleinopathies domain as the CSF biomarkers did for AD several

years ago. The results reported here support the fact that this method will be used in

conformations of alpha synuclein.

References

366

- 1. Cova I, Priori A. Diagnostic biomarkers for Parkinson's disease at a glance: where are
- we? J Neural Transm (Vienna Austria 1996) 2018;125:1417–32.
- 369 2. Mehra S. Sahay S. Maji SK, α-Synuclein misfolding and aggregation: Implications in
- Parkinson's disease pathogenesis. Biochim Biophys Acta BBA Proteins Proteomics
- 371 2019;1867:890–908.
- 372 3. Schmid AW, Fauvet B, Moniatte M, Lashuel HA. Alpha-synuclein Post-translational
- 373 Modifications as Potential Biomarkers for Parkinson Disease and Other
- 374 Synucleinopathies. Mol Cell Proteomics MCP 2013;12:3543–58.
- 4. Vinnakota RL, Yedlapudi D, Manda KM, Bhamidipati K, Bommakanti KT, RangaLakshmi
- GS, Kalivendi SV. Identification of an Alternatively Spliced α-Synuclein Isoform That
- Generates a 41-Amino Acid N-Terminal Truncated Peptide, 41-syn: Role in Dopamine
- Homeostasis. ACS Chem Neurosci 2018; 9:2948-58.
- 5. Mohaupt P, Roucou X, Delaby C, Vialaret J, Lehmann S, Hirtz C. The alternative
- proteome in neurobiology. Front Cell Neurosci 2022;16:1019680.
- 381 6. Kim TE, Newman AJ, Imberdis T, Brontesi L, Tripathi A, Ramalingam N, et al. Excess
- membrane binding of monomeric alpha-, beta- and gamma-synuclein is invariably
- associated with inclusion formation and toxicity. Hum Mol Genet 2021;30:2332–46.
- 7. Oeckl P, Metzger F, Nagl M, Von Arnim CA, Halbgebauer S, Steinacker P, et al. Alpha-,
- Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction
- 386 Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob
- 387 Disease but No Alteration in Synucleinopathies. Mol Cell Proteomics MCP
- 388 2016;15:3126–38.
- 8. Tsao HH, Huang CG, Wu YR. Detection and assessment of alpha-synuclein in Parkinson
- 390 disease. Neurochem Int 2022;158:105358.
- 9. Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, et al. Antibody-
- 392 based methods for the measurement of α-synuclein concentration in human

- cerebrospinal fluid method comparison and round robin study. J Neurochem 2019;149:
- 394 126–38.
- 10. Delaby C, Vialaret J, Hirtz C, Lefebvre T, Herkert M, Puy H, et al. Analytical comparison
- 396 of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill
- 397 patients. Bioanalysis 2021;13:1029–35.
- 398 11. Downard KM. 1912: a titanic year for mass spectrometry. J Mass Spectrom
- 399 2012;47:1034-9.
- 400 12. Vialaret J, Broutin S, Pugnier C, Santelé Sophie, Jaffuel A, Barnes A, et al. What sample
- 401 preparation should be chosen for targeted MS monoclonal antibody quantification in
- 402 human serum? Bioanalysis 2018;10:723–35.
- 13. Barkovits K, Kruse N, Linden A, Tönges L, Pfeiffer K, Mollenhauer B, Marcus K. Blood
- 404 Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein. Cells
- 405 2020;9:370.
- 406 14. Tönges L, Buhmann C, Klebe S, Klucken J, Kwon EH, Müller T et al. Blood-based
- 407 biomarker in Parkinson's disease: potential for future applications in clinical research and
- 408 practice. J Neural Transm 2022;129:1201–17.
- 409 15. Pons ML, Loftus N, Vialaret J, Moreau S, Lehmann S, Hirtz C. Proteomics Challenges for
- the Assessment of Synuclein Proteoforms as Clinical Biomarkers in Parkinson's Disease.
- 411 Front Aging Neurosci 2022;14:818606.
- 412 16. Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and
- disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of
- 414 Alzheimer's Disease. Alzheimers Res Ther 2019;11:34.
- 415 17. McGlinchey RP, Ni X, Shadish JA, Jiang J, Lee JC. The N terminus of α-synuclein
- dictates fibril formation. Proc Natl Acad Sci USA 2021;118: e2023487118.
- 417 18. Sorrentino ZA, Giasson Bl. The emerging role of α-synuclein truncation in aggregation
- 418 and disease. J Biol Chem 2020;295:10224–44.
- 419 19. Wenning GK, Krismer F. Chapter 19 Multiple system atrophy in Handbook of Clinical
- 420 Neurology. Elsevier 2013;117:229–41.

Psychiatry 1992;55:181-4.

424

425

426

20. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's
disease. Lancet Neurol 2021;20:385–97.
21. Hughes AJ, Daniel SE, Kilford L, Lees A J. Accuracy of clinical diagnosis of idiopathic

Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg

Table 1: Demographic and clinical characteristics of the plasma cohort. (UPDRS - Unified Parkinson's Disease

428 Rating Scale)

427

Disease group	PD	LBD	MSA	Control
Number of plasma samples	82	32	8	21
Mean age (years)	72.1	70.3	69.6	68.9
Sex (%M)	61.3	84.4	40	66.7
Disease duration (years)	8.44	5.48	3.73	2.57
Cognitive score (MMSE.				
MOC or MATIS) %				
Positive	30.5	50.0	9.4	9.5
Negative	17.1	37.5	87.5	52.4
N/A	52.4	12.5	3.1	38.1
Hoehn and Yahr stage				
(UPDRS V) %				
1	4.9	N/A	N/A	N/A
1.5	6.1	-		
2	45.1	-		
2.5	3.7	-		
3	32.9	1		
4	4.9	-		
N/A	2.4	-		

uantitation in plasma using LC-MRM

mary of the clinical performance for each peptide, ratio and combination from α -syn and α/β -syn peptides. NA means non assigned. AUC means ϵ

ptide sequence	Position on α-syn	Clinical performance in order : p value / sensibility / specificity / AUC (are				
		under the ROC curve)				
		PD vs LBD	PD vs MSA	PD vs control		
yn EGVVAAAEK	13-21	0.344 / NA / NA / NA	0.989 / NA / NA / NA	0.028 / 0.830 / 0.670		
				0.656		
n QGVAEAAGK	34-32	0.033 / 0.490 / 0.780 /	0.989 / NA / NA NA	0.001 / 0.830 / 0.760		
		0.629		0.726		
yn EGVLYVGSK	35-43	0.001 / 0.700 / 0.690 /	0.571 / NA / NA / NA	0.0001 / 0.840 / 0.760		
		0.694		0.787		
α-syn	61-80	0.710 / NA / NA / NA	0.372 / NA / NA / NA	0.021 / 0.870 / 0.670		
GGAVVTGVTAVAQK				0.664		
EGAGSIAAATGFVK	81-96	0.341 / NA / NA / NA	0.436 / NA / NA / NA	0.213 / NA / NA / NA		
EGVLYVGSK / α-syn	Peptide Ratio	0.0003 / 0.7 / 0.7 /	0.0084 / 0.80 / 0.85 /	>0.05 / NA / NA / NA		
GGAVVTGVTAVAQK		0.719	0.784			

uantitation in plasma using LC-MRM

(α-syn	Peptide	0.0001 / 0.7 / 0.68 /	0.0021 / 0.84 / 0.85 /	0.0003 / 0.83 / 0.58 /
GAVVTGVTAVAQK]*-	combination	0.743	0.831	0.757
1268) + (α/β-syn				
VGSK] * 0.0096545)				

Figure list

Figure 1: Workflow of the analysis of the synucleins peptides in plasma by liquid

chromatography-mass spectrometry with multiple reaction monitoring mode

Figure 2: Comparison of the PD group with the other synucleinpathies (MSA and

LBD) and the control group with the model (α-syn [EQVTNVGGAVVTGVTAVAQK]*-

 $0.011268 + \alpha/\beta$ -syn [EGVLYVGSK] * 0.0096545).

Figure 3A: ROC curve monitoring the clinical performance (sensitivity and specificity)

for the peptide combination when PD is compared to LBD patients.

Figure 3B: ROC curve monitoring the clinical performance (sensitivity and specificity)

for the peptide combination when PD is compared to MSA.

Conflict of Interest

The authors have no conflict of interest to report. Mass spectrometry experiments

were carried out using the facilities of the Montpellier Proteomics Platform (PPM-

PPC, BioCampus Montpellier). This article has been written in the context of the

"innovation center" of Shimadzu Europa GmbH. All figures were created with the

Biorender.com website.





